Mimedx Group Inc Financials
This page shows Mimedx Group Inc (MDXG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Mimedx Group Inc has an operating margin of 16.9%, meaning the company retains $17 of operating profit per $100 of revenue. This strong profitability earns a score of 84/100, reflecting efficient cost management and pricing power. This is up from 11.6% the prior year.
Mimedx Group Inc's revenue grew 8.5% year-over-year to $348.9M, a solid pace of expansion. This earns a growth score of 53/100.
Mimedx Group Inc carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.21, Mimedx Group Inc holds $4.21 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Mimedx Group Inc earns a strong 22.0% return on equity (ROE), meaning it generates $22 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 88/100. This is down from 40.8% the prior year.
Mimedx Group Inc scores 8.66, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($758.3M) relative to total liabilities ($70.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Mimedx Group Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Mimedx Group Inc generates $1.56 in operating cash flow ($66.2M OCF vs $42.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Mimedx Group Inc earns $14.9 in operating income for every $1 of interest expense ($58.9M vs $3.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Mimedx Group Inc generated $348.9M in revenue in fiscal year 2024. This represents an increase of 8.5% from the prior year.
Mimedx Group Inc's EBITDA was $62.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.6% from the prior year.
Mimedx Group Inc reported $42.4M in net income in fiscal year 2024. This represents a decrease of 27.2% from the prior year.
Mimedx Group Inc earned $0.28 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 24.3% from the prior year.
Mimedx Group Inc held $104.4M in cash against $17.8M in long-term debt as of fiscal year 2024.
Mimedx Group Inc had 147M shares outstanding in fiscal year 2024. This represents an increase of 0.5% from the prior year.
Mimedx Group Inc's gross margin was 82.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 0.2 percentage points from the prior year.
Mimedx Group Inc's operating margin was 16.9% in fiscal year 2024, reflecting core business profitability. This is up 5.3 percentage points from the prior year.
Mimedx Group Inc's net profit margin was 12.2% in fiscal year 2024, showing the share of revenue converted to profit. This is down 6.0 percentage points from the prior year.
Mimedx Group Inc's ROE was 22.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 18.8 percentage points from the prior year.
Mimedx Group Inc invested $12.3M in research and development in fiscal year 2024. This represents a decrease of 2.6% from the prior year.
Mimedx Group Inc spent $0 on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
MDXG Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $113.7M+15.3% | $98.6M+11.8% | $88.2M-5.1% | $92.9M+6.5% | $87.2M+2.9% | $84.7M-2.4% | $86.8M+6.3% | $81.7M |
| Cost of Revenue | $18.7M+0.2% | $18.7M+12.8% | $16.6M-2.1% | $16.9M+13.8% | $14.9M+14.4% | $13.0M-6.2% | $13.8M-6.4% | $14.8M |
| Gross Profit | $95.0M+18.9% | $79.9M+11.6% | $71.6M-5.7% | $76.0M+5.0% | $72.4M+0.9% | $71.7M-1.7% | $73.0M+9.1% | $66.9M |
| R&D Expenses | $3.7M+12.1% | $3.3M-0.8% | $3.3M-6.8% | $3.6M+18.5% | $3.0M+6.0% | $2.8M+16.7% | $2.4M-20.8% | $3.1M |
| SG&A Expenses | $69.0M+7.6% | $64.2M+7.0% | $60.0M-1.8% | $61.0M+10.2% | $55.4M+0.5% | $55.1M+1.4% | $54.3M+3.4% | $52.6M |
| Operating Income | $22.2M+79.4% | $12.4M+49.9% | $8.3M-25.4% | $11.1M-52.9% | $23.4M+77.7% | $13.2M-14.8% | $15.5M+39.3% | $11.1M |
| Interest Expense | $425K-10.5% | $475K-0.6% | $478K-8.3% | $521K-0.2% | $522K-78.0% | $2.4M-79.2% | $11.4M+780.8% | -$1.7M |
| Income Tax | $6.1M+80.0% | $3.4M+113.3% | $1.6M-58.3% | $3.8M-31.9% | $5.6M+138.3% | $2.3M+106.3% | -$37.4M-6423.9% | $591K |
| Net Income | $16.7M+74.1% | $9.6M+37.0% | $7.0M-5.6% | $7.4M-57.8% | $17.6M+90.3% | $9.3M-82.7% | $53.5M+526.6% | $8.5M |
| EPS (Diluted) | $0.11+83.3% | $0.06+20.0% | $0.050.0% | $0.05-58.3% | $0.12+100.0% | $0.06-83.3% | $0.36+500.0% | $0.06 |
MDXG Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $319.0M+9.6% | $291.1M+7.7% | $270.4M+2.5% | $263.9M+14.7% | $230.2M+3.8% | $221.7M-7.3% | $239.0M+26.5% | $189.0M |
| Current Assets | $254.1M+15.0% | $220.9M+10.4% | $200.1M+4.3% | $191.9M+24.6% | $154.0M+10.9% | $138.9M-15.5% | $164.3M+6.3% | $154.5M |
| Cash & Equivalents | $142.1M+19.5% | $118.9M+11.7% | $106.4M+1.9% | $104.4M+51.2% | $69.0M+42.4% | $48.5M-40.9% | $82.0M+1.0% | $81.2M |
| Inventory | $26.5M+6.5% | $24.9M+3.4% | $24.1M+1.1% | $23.8M-5.0% | $25.1M+2.5% | $24.5M+16.3% | $21.0M+10.2% | $19.1M |
| Accounts Receivable | $78.2M+12.9% | $69.2M+11.1% | $62.3M+11.6% | $55.8M+5.7% | $52.8M-7.4% | $57.0M+5.8% | $53.9M+9.9% | $49.0M |
| Goodwill | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M |
| Total Liabilities | $80.0M+7.5% | $74.5M+10.1% | $67.6M-4.5% | $70.8M+13.9% | $62.1M-5.8% | $66.0M-31.5% | $96.3M-48.7% | $187.7M |
| Current Liabilities | $57.7M+14.7% | $50.3M+18.0% | $42.6M-6.5% | $45.6M+14.0% | $40.0M-5.2% | $42.2M-8.2% | $46.0M+5.5% | $43.6M |
| Long-Term Debt | $16.8M-2.2% | $17.2M-1.8% | $17.5M-1.7% | $17.8M-2.3% | $18.2M-1.1% | $18.5M-61.6% | $48.1M-1.8% | $49.0M |
| Total Equity | $238.9M+10.3% | $216.6M+6.8% | $202.8M+5.0% | $193.1M+14.9% | $168.0M+7.9% | $155.7M+9.1% | $142.7M+10630.6% | $1.3M |
| Retained Earnings | -$57.9M+22.4% | -$74.6M+11.4% | -$84.2M+7.7% | -$91.3M+14.5% | -$106.8M+14.2% | -$124.4M+6.9% | -$133.7M+28.6% | -$187.2M |
MDXG Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $29.3M+103.4% | $14.4M+172.1% | $5.3M-71.8% | $18.8M-13.9% | $21.8M+264.9% | $6.0M-41.7% | $10.3M-19.8% | $12.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $427K-32.0% | $628K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $9.8M-19.2% | $12.2M |
| Investing Cash Flow | -$5.3M-492.8% | -$887K-118.5% | -$406K+85.3% | -$2.8M-205.7% | -$905K+85.0% | -$6.0M-1152.4% | -$481K+25.9% | -$649K |
| Financing Cash Flow | -$857K+21.7% | -$1.1M+62.0% | -$2.9M-619.5% | -$400K-11.4% | -$359K+98.9% | -$33.5M-274.4% | -$8.9M-2516.2% | $370K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MDXG Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.5%+2.5pp | 81.0%-0.2pp | 81.2%-0.6pp | 81.8%-1.2pp | 83.0%-1.7pp | 84.7%+0.6pp | 84.1%+2.2pp | 81.9% |
| Operating Margin | 19.5%+7.0pp | 12.6%+3.2pp | 9.3%-2.5pp | 11.9%-15.0pp | 26.9%+11.3pp | 15.6%-2.3pp | 17.8%+4.2pp | 13.6% |
| Net Margin | 14.7%+5.0pp | 9.8%+1.8pp | 8.0%-0.1pp | 8.0%-12.2pp | 20.2%+9.3pp | 10.9%-50.7pp | 61.6%+51.1pp | 10.4% |
| Return on Equity | 7.0%+2.6pp | 4.4%+1.0pp | 3.5%-0.4pp | 3.9%-6.6pp | 10.5%+4.5pp | 5.9%-31.5pp | 37.5%-604.2pp | 641.6% |
| Return on Assets | 5.3%+1.9pp | 3.3%+0.7pp | 2.6%-0.2pp | 2.8%-4.8pp | 7.7%+3.5pp | 4.2%-18.2pp | 22.4%+17.9pp | 4.5% |
| Current Ratio | 4.41+0.0 | 4.39-0.3 | 4.70+0.5 | 4.21+0.4 | 3.85+0.6 | 3.29-0.3 | 3.57+0.0 | 3.54 |
| Debt-to-Equity | 0.070.0 | 0.080.0 | 0.090.0 | 0.09-0.0 | 0.110.0 | 0.12-0.2 | 0.34-36.5 | 36.82 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | 11.3%-3.6pp | 14.9% |
Similar Companies
Frequently Asked Questions
What is Mimedx Group Inc's annual revenue?
Mimedx Group Inc (MDXG) reported $348.9M in total revenue for fiscal year 2024. This represents a 8.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Mimedx Group Inc's revenue growing?
Mimedx Group Inc (MDXG) revenue grew by 8.5% year-over-year, from $321.5M to $348.9M in fiscal year 2024.
Is Mimedx Group Inc profitable?
Yes, Mimedx Group Inc (MDXG) reported a net income of $42.4M in fiscal year 2024, with a net profit margin of 12.2%.
What is Mimedx Group Inc's earnings per share (EPS)?
Mimedx Group Inc (MDXG) reported diluted earnings per share of $0.28 for fiscal year 2024. This represents a -24.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Mimedx Group Inc's EBITDA?
Mimedx Group Inc (MDXG) had EBITDA of $62.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Mimedx Group Inc have?
As of fiscal year 2024, Mimedx Group Inc (MDXG) had $104.4M in cash and equivalents against $17.8M in long-term debt.
What is Mimedx Group Inc's gross margin?
Mimedx Group Inc (MDXG) had a gross margin of 82.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Mimedx Group Inc's operating margin?
Mimedx Group Inc (MDXG) had an operating margin of 16.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Mimedx Group Inc's net profit margin?
Mimedx Group Inc (MDXG) had a net profit margin of 12.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Mimedx Group Inc's return on equity (ROE)?
Mimedx Group Inc (MDXG) has a return on equity of 22.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Mimedx Group Inc's operating cash flow?
Mimedx Group Inc (MDXG) generated $66.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Mimedx Group Inc's total assets?
Mimedx Group Inc (MDXG) had $263.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Mimedx Group Inc spend on research and development?
Mimedx Group Inc (MDXG) invested $12.3M in research and development during fiscal year 2024.
How many shares does Mimedx Group Inc have outstanding?
Mimedx Group Inc (MDXG) had 147M shares outstanding as of fiscal year 2024.
What is Mimedx Group Inc's current ratio?
Mimedx Group Inc (MDXG) had a current ratio of 4.21 as of fiscal year 2024, which is generally considered healthy.
What is Mimedx Group Inc's debt-to-equity ratio?
Mimedx Group Inc (MDXG) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mimedx Group Inc's return on assets (ROA)?
Mimedx Group Inc (MDXG) had a return on assets of 16.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Mimedx Group Inc's Altman Z-Score?
Mimedx Group Inc (MDXG) has an Altman Z-Score of 8.66, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Mimedx Group Inc's Piotroski F-Score?
Mimedx Group Inc (MDXG) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mimedx Group Inc's earnings high quality?
Mimedx Group Inc (MDXG) has an earnings quality ratio of 1.56x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Mimedx Group Inc cover its interest payments?
Mimedx Group Inc (MDXG) has an interest coverage ratio of 14.9x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Mimedx Group Inc?
Mimedx Group Inc (MDXG) scores 85 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.